NewAmsterdam Pharma Co NV
NAMSHealthcare|Biotechnology|Netherlands
$35.30
-0.66 (-1.84%)
Tangible Book
$5.70
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07219602 A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Lipidemia, Type 2 Diabetes (T2DM) | P3 | Recruiting | 300 | RCT, Double-blind | obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg |
| NCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Atherosclerotic Cardiovascular Disease | P3 | Active | 9,541 | RCT, Double-blind | Obicetrapib, Placebo |
| NCT06305559 A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Lipidemia, Coronary Artery Disease | P3 | Active | 300 | RCT, Double-blind | obicetrapib 10 mg + ezetimibe 10 mg FDC daily |
| NCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias | P2 | Recruiting | 69 | Open-label | obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks |
| NCT06982508 Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | Antioxidant Absorption | P2 | Recruiting | 100 | RCT, Double-blind | Obicetrapib 10mg, Placebo |
| NCT05972278 Investigating the Effect of Obicetrapib on Lipoprotein Metabolism | Lipid Metabolism | P1 | Active | 22 | RCT, Double-blind | Obicetrapib |
| NCT07478887 Impact of the Corrie Lipids Digital Health Program on Lipid Optimization | Cardiovascular Risk, LDL-C | N/A | Recruiting | 1,000 | Open-label | — |
| NCT05425745 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | Dyslipidemias, High Cholesterol | P3 | Completed | 354 | RCT, Double-blind | Obicetrapib, Placebo |
| NCT06005597 Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | Dyslipidemias, Hypercholesterolemia | P3 | Completed | 407 | RCT, Double-blind | Monotherapy obicetrapib, Monotherapy ezetimibe |
| NCT05142722 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | Dyslipidemias, High Cholesterol | P3 | Completed | 2,530 | RCT, Double-blind | Placebo, Obicetrapib |
| NCT05421078 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | Dyslipidemia, Hypercholesterolemia | P2 | Completed | 102 | RCT, Double-blind | Obicetrapib, Placebo |
| NCT05266586 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | Dyslipidemias, High Cholesterol | P2 | Completed | 119 | RCT, Double-blind | Obicetrapib, Ezetimibe 10mg |
| NCT04753606 Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | Dyslipidemias, High Cholesterol | P2 | Completed | 120 | RCT, Double-blind | Obicetrapib |
| NCT04770389 Randomized Study of Obicetrapib in Combination With Ezetimibe | Dyslipidemias, High Cholesterol | P2 | Completed | 112 | RCT, Double-blind | Obicetrapib 5mg, Ezetimibe 10mg |
| NCT05161715 Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | Early Alzheimer's Disease | P2 | Completed | 13 | Open-label | Obicetrapib |
| NCT06081166 A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin | Healthy Volunteers | P1 | Completed | 74 | Open-label | Obicetrapib, Atorvastatin Calcium, Rosuvastatin Calcium |
| NCT06250205 Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib | Healthy Volunteers | P1 | Completed | 30 | Open-label | Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC) |
| NCT06547359 A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects | Healthy Volunteers | P1 | Completed | 94 | Open-label | Obicetrapib 10mg, Ezetimibe 10mg |
| NCT06048302 PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | Hepatic Impairment, Healthy | P1 | Completed | 18 | Open-label | Obicetrapib |
| NCT06050291 Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe | Healthy Volunteer Study | P1 | Completed | 28 | RCT, Open-label | Fixed-Dose Combination (FDC) Tablet |